Fate Therapeutics
FATE
16 hedge funds and large institutions have $24.7M invested in Fate Therapeutics in 2013 Q4 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.54M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$5.43M |
| 3 |
O
OrbiMed
New York
|
+$4.42M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$3.43M |
| 5 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$1.91M |
Top Sellers
FATE Hedge Fund Activity: Q4 2013 in Review
16 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q4 2013, worth a combined $24.7M.
Buyers outnumbered sellers: 16 funds opened new FATE positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $7.54M.
- 16 institutional investors held Fate Therapeutics (FATE) as of Q4 2013, up from 0 in Q3 2013.
- Funds reported $24.7M of Fate Therapeutics stock for Q4 2013.
- 16 funds opened new Fate Therapeutics positions in Q4 2013 and 0 closed out, a net change of +16 holders.
- The largest Fate Therapeutics buyer in Q4 2013 was Wellington Management Group, an estimated $7.54M added.
Based on aggregated 13F filings for Q4 2013.